Therapeutically, targeting extracellular BAG3 with monoclonal neutralizing antibodies in murine pancreatic adenocarcinoma models reduced fibrosis and macrophage infiltration, resulting in inhibited tumor progression (37, 45). This evidence concerns the gene BAG3 and neoplasm.